AAAAAA

   
Results: 1-8 |
Results: 8
INDUCTION IMMUNOTHERAPY IN HEART-TRANSPLANTATION WITH T101B9.1A-31 - A PHASE-I STUDY
Authors: WAID TH THOMPSON JS MCKEOWN JW BROWN SA SEKELA ME
Citation: Th. Waid et al., INDUCTION IMMUNOTHERAPY IN HEART-TRANSPLANTATION WITH T101B9.1A-31 - A PHASE-I STUDY, The Journal of heart and lung transplantation, 16(9), 1997, pp. 913-916
TREATMENT OF RENAL-ALLOGRAFT REJECTION WITH T10B9.1A31 OR OKT3 - FINAL ANALYSIS OF A PHASE-II CLINICAL-TRIAL
Authors: WAID TH LUCAS BA THOMPSON JS MCKEOWN JW BROWN S KRYSCIO R SKEETERS LJ
Citation: Th. Waid et al., TREATMENT OF RENAL-ALLOGRAFT REJECTION WITH T10B9.1A31 OR OKT3 - FINAL ANALYSIS OF A PHASE-II CLINICAL-TRIAL, Transplantation, 64(2), 1997, pp. 274-281
T10B9 (MEDI-500) MEDIATED IMMUNOSUPPRESSION - STUDIES ON THE MECHANISM OF ACTION
Authors: BROWN SA LUCAS BA WAID TH MCKEOWN JW BARVE S JACKSON LR THOMPSON JS
Citation: Sa. Brown et al., T10B9 (MEDI-500) MEDIATED IMMUNOSUPPRESSION - STUDIES ON THE MECHANISM OF ACTION, Clinical transplantation, 10(6), 1996, pp. 607-613
SEVERE INFECTION OCCURS LESS FREQUENTLY IN RENAL-ALLOGRAFT RECIPIENTSTREATED FOR REJECTION WITH T10B9.1A-31 THAN IN OKT3-TREATED PATIENTS
Authors: WAID TH THOMPSON JS LUCAS BA MCKEOWN JW
Citation: Th. Waid et al., SEVERE INFECTION OCCURS LESS FREQUENTLY IN RENAL-ALLOGRAFT RECIPIENTSTREATED FOR REJECTION WITH T10B9.1A-31 THAN IN OKT3-TREATED PATIENTS, Journal of the American Society of Nephrology, 6(3), 1995, pp. 1120-1120
CYTOMEGALOVIRUS HYPERIMMUNE GLOBULIN FOR CMV DISEASE REFRACTORY TO GANCICLOVIR IN RENAL-TRANSPLANTATION
Authors: WAID TH MCKEOWN JW
Citation: Th. Waid et Jw. Mckeown, CYTOMEGALOVIRUS HYPERIMMUNE GLOBULIN FOR CMV DISEASE REFRACTORY TO GANCICLOVIR IN RENAL-TRANSPLANTATION, Transplantation proceedings, 27(5), 1995, pp. 46-46
IMPROVED GRAFT AND PATIENT SURVIVAL WITH T10B9.1A-31 OR OKT3 MONOCLONAL-ANTIBODY FOR TREATMENT FOR PRIMARY REJECTION
Authors: WAID TH LUCAS BA THOMPSON JS MCKEOWN JW BROWN SA
Citation: Th. Waid et al., IMPROVED GRAFT AND PATIENT SURVIVAL WITH T10B9.1A-31 OR OKT3 MONOCLONAL-ANTIBODY FOR TREATMENT FOR PRIMARY REJECTION, Journal of the American Society of Nephrology, 5(3), 1994, pp. 1042-1042
T10B9.1A-31 EFFECTIVELY REVERSES RENAL-ALLOGRAFT REJECTION CRISES WITH FEWER SIDE-EFFECTS, LESS CYTOKINE RELEASE AND NO SEVERE INFECTIONS
Authors: WAID TH LUCAS BA THOMPSON JS MCKEOWN JW BROWN SA
Citation: Th. Waid et al., T10B9.1A-31 EFFECTIVELY REVERSES RENAL-ALLOGRAFT REJECTION CRISES WITH FEWER SIDE-EFFECTS, LESS CYTOKINE RELEASE AND NO SEVERE INFECTIONS, Journal of the American Society of Nephrology, 5(3), 1994, pp. 1042-1042
ACUTE EFFECTS OF GENTAMICIN ON THICK ASCENDING LIMB FUNCTION IN THE RAT
Authors: KIDWELL DT MCKEOWN JW GRIDER JS MCCOMBS GB OTT CE JACKSON BA
Citation: Dt. Kidwell et al., ACUTE EFFECTS OF GENTAMICIN ON THICK ASCENDING LIMB FUNCTION IN THE RAT, European journal of pharmacology. Environmental toxicology and pharmacology section, 270(1), 1994, pp. 97-103
Risultati: 1-8 |